Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Convertible Debt (2017 - 2025)

Guided Therapeutics' Convertible Debt history spans 12 years, with the latest figure at $35000.0 for Q1 2025.

  • On a quarterly basis, Convertible Debt fell 96.9% to $35000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $35000.0, a 96.9% decrease, with the full-year FY2024 number at $14000.0, changed N/A from a year prior.
  • Convertible Debt hit $35000.0 in Q1 2025 for Guided Therapeutics, up from $14000.0 in the prior quarter.
  • Over the last five years, Convertible Debt for GTHP hit a ceiling of $1.1 million in Q1 2024 and a floor of $14000.0 in Q4 2024.
  • Historically, Convertible Debt has averaged $620090.9 across 5 years, with a median of $820000.0 in 2021.
  • Biggest five-year swings in Convertible Debt: surged 797.06% in 2021 and later tumbled 96.9% in 2025.
  • Tracing GTHP's Convertible Debt over 5 years: stood at $820000.0 in 2021, then grew by 27.56% to $1.0 million in 2022, then fell by 6.12% to $982000.0 in 2023, then tumbled by 98.57% to $14000.0 in 2024, then surged by 150.0% to $35000.0 in 2025.
  • Business Quant data shows Convertible Debt for GTHP at $35000.0 in Q1 2025, $14000.0 in Q4 2024, and $162000.0 in Q3 2024.